同类首创引领骨髓纤维化治疗新时代,正大天晴罗伐昔替尼获批上市

CPHI制药在线
Mar 02

关注并星标CPHI制药在线2月28日,NMPA官网发布重磅公告,正大天晴药业集团自主研发的1类新药罗伐昔替尼片(Rovadicitinib,TQ05105) 正式获批,用于中危-2或高危原发性骨髓纤维化(PMF)、真性红细胞增多症后骨髓纤维化(PPV-MF)、原发性血小板增多症后骨髓纤维化(PET-MF)成人患者一线治疗,用于改善疾病相关脾肿大与全身症状。罗伐昔替尼是正大天晴历时十余年自主研发的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10